Jump to content

Holoclar

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AnomieBOT (talk | contribs) at 13:24, 20 February 2016 (Dating maintenance tags: {{Expand-section}}). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Holoclar is a stem cell therapy for people with severe limbal stem cell deficiency due to burns in the eye.[1][2]

Its approval in 2015 by the European Commission was the first time that a stem cell therapy, other than the use of umbilical cord stem cells, was allowed to be sold by any regulatory agency in the world.[3]

It works by seeding stem cells to promote the regrowth of the cornea.[3][4]

Manufacturing and logistics

Once cultured at the lab in Germany the cells must be implanted within 36 hours.[5]

See also

References

  1. ^ European Medicines Agency. "First stem-cell therapy recommended for approval in EU". Retrieved 3 March 2015.
  2. ^ Knapton, Sarah (19 December 2014). "First stem-cell therapy approved for medical use in Europe". The Telegraph. Retrieved 3 March 2015.
  3. ^ a b Abbott, Alison (3 March 2015). "Behind the scenes of the world's first commercial stem-cell therapy". Nature News. Retrieved 3 March 2015.
  4. ^ Pellegrini G, Rama P, Di Rocco A, Panaras A, De Luca M (2014). "Concise review: hurdles in a successful example of limbal stem cell-based regenerative medicine". Stem Cells. 32 (1): 26–34. doi:10.1002/stem.1517. PMID 24038592.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Short shelf-life poses problems for cell therapy makers, Chiesi